Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more
Agios Pharmaceuticals, Inc. (0HB0) - Net Assets
Latest net assets as of September 2025: $1.28 Billion USD
Based on the latest financial reports, Agios Pharmaceuticals, Inc. (0HB0) has net assets worth $1.28 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.39 Billion) and total liabilities ($101.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.28 Billion |
| % of Total Assets | 92.68% |
| Annual Growth Rate | 25.4% |
| 5-Year Change | 285.72% |
| 10-Year Change | 346.5% |
| Growth Volatility | 79.05 |
Agios Pharmaceuticals, Inc. - Net Assets Trend (2012–2024)
This chart illustrates how Agios Pharmaceuticals, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Agios Pharmaceuticals, Inc. (2012–2024)
The table below shows the annual net assets of Agios Pharmaceuticals, Inc. from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.54 Billion | +90.00% |
| 2023-12-31 | $811.02 Million | -26.33% |
| 2022-12-31 | $1.10 Billion | -14.80% |
| 2021-12-31 | $1.29 Billion | +223.40% |
| 2020-12-31 | $399.50 Million | -37.63% |
| 2019-12-31 | $640.53 Million | -6.84% |
| 2018-12-31 | $687.54 Million | +83.10% |
| 2017-12-31 | $375.50 Million | +4.72% |
| 2016-12-31 | $358.59 Million | +3.90% |
| 2015-12-31 | $345.12 Million | -19.89% |
| 2014-12-31 | $430.81 Million | +162.25% |
| 2013-12-31 | $164.28 Million | +61.22% |
| 2012-12-31 | $101.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Agios Pharmaceuticals, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7488700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $73.00K | 0.00% |
| Other Comprehensive Income | $-1.52 Million | -0.10% |
| Other Components | $1.69 Billion | 109.76% |
| Total Equity | $1.54 Billion | 100.00% |
Agios Pharmaceuticals, Inc. Competitors by Market Cap
The table below lists competitors of Agios Pharmaceuticals, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing Yunhai Special Metals Co Ltd
SHE:002182
|
$1.49 Billion |
|
REA Group Limited
PINK:RPGRY
|
$1.49 Billion |
|
RED CAT HDGS INC.DL -001
F:BQ73
|
$1.49 Billion |
|
John Wiley & Sons B
NYSE:WLYB
|
$1.50 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
$1.49 Billion |
|
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
|
$1.49 Billion |
|
NRW Holdings Ltd
AU:NWH
|
$1.49 Billion |
|
NAPCO Security Technologies Inc
NASDAQ:NSSC
|
$1.49 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Agios Pharmaceuticals, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 811,019,000 to 1,540,956,000, a change of 729,937,000 (90.0%).
- Net income of 673,725,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,077,000.
- Other factors increased equity by 57,289,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $673.73 Million | +43.72% |
| Other Comprehensive Income | $-1.08 Million | -0.07% |
| Other Changes | $57.29 Million | +3.72% |
| Total Change | $- | 90.00% |
Book Value vs Market Value Analysis
This analysis compares Agios Pharmaceuticals, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.25x to 1.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $12.90 | $29.01 | x |
| 2013-12-31 | $8.53 | $29.01 | x |
| 2014-12-31 | $12.60 | $29.01 | x |
| 2015-12-31 | $9.22 | $29.01 | x |
| 2016-12-31 | $9.16 | $29.01 | x |
| 2017-12-31 | $8.06 | $29.01 | x |
| 2018-12-31 | $11.97 | $29.01 | x |
| 2019-12-31 | $10.68 | $29.01 | x |
| 2020-12-31 | $5.79 | $29.01 | x |
| 2021-12-31 | $21.37 | $29.01 | x |
| 2022-12-31 | $20.09 | $29.01 | x |
| 2023-12-31 | $14.57 | $29.01 | x |
| 2024-12-31 | $26.62 | $29.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Agios Pharmaceuticals, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 43.72%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1845.92%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.08x
- Recent ROE (43.72%) is above the historical average (-40.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -62.17% | -108.71% | 0.18x | 3.12x | $-31.68 Million |
| 2013 | -33.14% | -170.54% | 0.13x | 1.53x | $-56.72 Million |
| 2014 | -12.61% | -81.86% | 0.13x | 1.16x | $-95.94 Million |
| 2015 | -34.11% | -199.14% | 0.14x | 1.22x | $-152.24 Million |
| 2016 | -55.35% | -283.97% | 0.11x | 1.73x | $-234.33 Million |
| 2017 | -83.80% | -731.60% | 0.07x | 1.64x | $-352.22 Million |
| 2018 | -50.33% | -366.61% | 0.11x | 1.25x | $-414.78 Million |
| 2019 | -64.24% | -348.97% | 0.13x | 1.39x | $-475.52 Million |
| 2020 | -81.94% | 0.00% | 0.00x | 2.14x | $-367.32 Million |
| 2021 | -29.75% | 0.00% | 0.00x | 1.11x | $-513.62 Million |
| 2022 | -21.06% | -1627.82% | 0.01x | 1.13x | $-341.88 Million |
| 2023 | -43.41% | -1312.63% | 0.03x | 1.16x | $-433.19 Million |
| 2024 | 43.72% | 1845.92% | 0.02x | 1.08x | $519.63 Million |
Industry Comparison
This section compares Agios Pharmaceuticals, Inc.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. (0HB0) | $1.28 Billion | -62.17% | 0.08x | $1.49 Billion |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |